Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of careThe as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall responseLonger-term data from CARTITUDE-2 showed deep and durable respons...
PRINCETON, N.J.--(BUSINESS WIRE)--Dec 10, 2023--
Seven new agents have received FDA approval since October 2022.
"A significant wave [of JN.1] has started here and could be blunted with a high booster rate and mitigation measures."
(BPT) - When the COVID-19 pandemic hit in 2020, Ben, who had already been diagnosed with clinical depression in 2018, felt his depressive symptoms increase the more isolated he became.